Meeting Coverage:

American Academy of Ophthalmology

AAO: 2023

Two Years of Treatment with Avacincaptad Pegol

Show Description +

Arshad M. Khanani, MD, MA, discusses 2-year data from the GATHER2 trial, with patients re-randomized in the second year to monthly or every-other-month treatment with avacincaptad pegol (Izervay, Iveric Bio/Astellas) or sham.

Posted: 11/08/2023

Up Next


Genetics: Now or Later

Inas Aboobakar, MD

Drug-Eluting IOLs

Kenneth Mandell, MD, PhD

Pearls for Subretinal Gene Therapy

Christina Y. Weng, MD, MBA

A CRISPR Gene Editing Update

Glenn Yiu, MD, PhD

A New Approach to Combatting Blindness in RP

Russell N. Van Gelder, MD, PhD

Diversity in Ocular Oncology

Basil K. Williams Jr, MD

Update on Glaucoma Lasers

Aaki Shukla, MD, and Mary Qiu, MD

Two Years of Treatment with Avacincaptad Pegol

Arshad M. Khanani, MD, MA, discusses 2-year data from the GATHER2 trial, with patients re-randomized in the second year to monthly or every-other-month treatment with avacincaptad pegol (Izervay, Iveric Bio/Astellas) or sham.

Posted: 11/08/2023


Please log in to leave a comment.

More From AAO: 2023 Coverage